Vertex Pharmaceuticals announced a broad reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor). This agreement follows a positive final draft recommendation from the National Institute for Health and Care Excellence (NICE).
This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. All eligible CF patients in England can now benefit from this medicine.
This agreement represents a significant milestone in Vertex's efforts to further improve the lives of people with CF. ALYFTREK demonstrated the potential for even better outcomes for patients than KAFTRIO in pivotal studies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.